Navigation Links
AGH Cardiovascular Team Explores Implantable Device Designed to Treat Congestive Heart Failure
Date:10/22/2013

Pittsburgh, PA (PRWEB) October 22, 2013

Allegheny General Hospital (AGH), an affiliate of the Allegheny Health Network, is enrolling patients in a landmark clinical trial to explore the use of a promising investigational technology designed to treat congestive heart failure by stimulating the body’s natural mechanism for blood pressure regulation.

The Barostim HOPE4HF clinical trial will evaluate the effectiveness and safety of Barostim neo, a second generation implantable device that electrically activates the baroreceptors, the body’s natural blood pressure sensors that regulate heart function. The system is designed to signal the brain to relax the arteries to facilitate blood flow, slow the heart allowing more time for it to fill with blood, and prompt the kidneys to reduce fluid in the body, reducing the heart’s workload. This, in turn, is designed to improve heart function and reduce heart failure symptoms.

“Barostim Therapy initially was studied in more than 500 patients with excellent results,” said Srinivas Murali, MD, Director of Allegheny General’s Division of Cardiovascular Medicine and Medical Director of the hospital’s Cardiovascular Institute. “With a new system that’s smaller and more easily placed, we hope to see even further improved patient outcomes.”

Perfecting a device that can help the heart work more efficiently would be an important advance for the 5.1 million adults living with heart failure in the US. Statistics show that 670,000 new cases are diagnosed each year and more than 277,000 people die annually of the disease. In western Pennsylvania and in the rest of the country, heart failure is the leading cause of hospitalization for those over the age of 65.

In heart failure, the heart cannot pump enough blood to support the body. Impaired heart function results in shortness of breath, exercise intolerance and fluid retention. Those with heart failure are six to nine times more likely to experience sudden cardiac death than their healthy counterparts.

Barostim neo is a pacemaker-like device consisting of two parts: a small pulse generator implanted under the collar bone which is connected by a think wire to a small lead implanted unilaterally either on the left or the right carotid artery. An external programmer is used by doctors to non-invasively transmit and regulate energy from the generator to the small lead.

Barostim neo is adjustable to each patient’s unique needs. The device operates automatically and continuously, eliminating the possibility of noncompliance with treatment recommendations.

Barostim neo was developed by CVRx, Inc., a privately held company based in Minneapolis.

The device achieved promising clinical results in European studies. AGH and a handful of other elite US medical centers will be enrolling up to sixty patients in the American study.

To enroll, patients must have a left ventricular ejection fraction less than or equal to 35 percent and be classified as having New York Heart Association Class III Heart Failure.

For more information on the study, contact Sheila Bernardini, RN, Research Coordinator, at 412-359-3281or sbernard(at)wpahs(dot)org or visit the study website at http://www.HeartfailureTrial.com.

###

About AGH Cardiovascular Institute: Allegheny General Hospital’s Cardiovascular Institute offers comprehensive, state-of-the-art care for the complete spectrum of cardiovascular disease. The Institute’s nationally recognized medical staff includes specialists in general and interventional cardiology, electrophysiology, leading edge diagnostic cardiology – including cardiovascular MRI, CT and 3-D echocardiography - women’s heart care, heart failure and pulmonary hypertension, heart transplantation and mechanical circulatory support, vascular surgery and wound care, thoracic surgery, heart valve disease and coronary artery bypass surgery.

The hospital’s broad scope of advanced capabilities in the treatment of heart failure offers patients access to cutting edge investigational therapies being explored in clinical trials, such as new medicines and implantable devices designed to more effectively monitor disease progression and treat conditions before they require hospitalization.

About the Allegheny Health Network:
Allegheny Health Network is an integrated healthcare delivery system serving the Western Pennsylvania region. The Network is comprised of eight hospitals, including its flagship academic medical center Allegheny General Hospital, Allegheny Valley Hospital, Canonsburg Hospital, Forbes Hospital, Jefferson Hospital, Saint Vincent Hospital, Westfield Memorial Hospital and West Penn Hospital; the Allegheny-Singer Research Institute; a soon-to open medical mall; and a healthcare group purchasing organization. The Network employs approximately 17,000 people, including more than 2,100 physicians on its medical staff. The Network also serves as a clinical campus for both Temple University School of Medicine and Drexel University College of Medicine.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11251910.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
2. Is it time for regional cardiovascular emergency care systems across the US?
3. New guidelines deliver concise messages for implementing cardiovascular prevention
4. Meditation practice may decrease risk for cardiovascular disease in teens
5. Meditation practice may decrease risk for cardiovascular disease in teens
6. Exercise program improved health of lung transplant patients and cut cardiovascular risk
7. Low steroid levels linked to increased risk of cardiovascular disease
8. Prostate cancer treatment regret is 52 percent higher in men with cardiovascular disease
9. Prevention is better than cure for killer cardiovascular disease
10. Increased cardiovascular risk in HIV-infected patients may relate to arterial inflammation
11. NIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: